Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Stay Informed: Medical and Research Updates
Connect With Us! Visit the Children's Corner for Macular Degeneration
 

 

Targeting Cholesterol Buildup Slowed Macular Degeneration Vision Loss In Mice

BrightFocus-Funded Research Could Lead To New Treatment For Eye Disease

April 5, 2013
Source: Cell Metabolism

Research Summary:

Dr. Apte
Dr. Apte

Both age-related macular degeneration (AMD) and atherosclerosis have a common problem—an inability to remove a buildup of fat and cholesterol. In AMD, this buildup takes the form of drusen deposits in the retina. The senior and lead authors of this groundbreaking publication, BrightFocus-funded Rajendra Apte, M.D., Ph.D., and Abdoulaye Sene, Ph.D., have pinpointed that a particular protein, called ABCA1, is required by immune cells, called macrophages, to clear cholesterol after they have “eaten” drusen in an effort to clean up the retina. The researchers believe that as humans and mice age, the levels of ABCA1 in macrophages are reduced, making them unable to properly chew up and spit out the unwanted deposits caused by runaway inflammation, leading to vision loss from abnormal vessel growth in wet AMD.

Dr. Sene
Dr. Sene

The researchers then found that an ABCA1-restoring drug, called an LXR agonist, could reduce the levels of cholesterol in cultured macrophage cells from AMD patients. In addition, the drug was delivered in eye drop format into the eyes of older mice with AMD, reducing both the levels of cholesterol and the number of damaging blood vessels. They chose to deliver the drug by eye drops to reduce the safety risks, because there have been concerns about potential toxic effects on the liver when the same drug has been delivered by mouth in other studies with mice.

Significance:

Medications to lower cholesterol are currently prescribed to treat atherosclerosis and help keep arteries clear. This study suggests that some of those same drugs could be modified and repackaged in an eye drop format, to test as future early-stage treatments for age-related macular degeneration.

Macular degeneration causes deterioration of the macula, the central area of the retina.

Beneath the retina of a patient with macular degeneration, the small light dots against the orange background are cholesterol deposits, and as cholesterol builds up, the area becomes inflamed, spurring the development of abnormal blood vessels that can lead to loss of vision. Source: Apte laboratory.

A new study raises the intriguing possibility that drugs prescribed to lower cholesterol may be effective against macular degeneration, a blinding eye disease.

Researchers at Washington University School of Medicine in St. Louis have found that age-related macular degeneration, the leading cause of vision loss in Americans over 50, shares a common link with atherosclerosis. Both problems have the same underlying defect: the inability to remove a buildup of fat and cholesterol.

The new study is published online in the journal Cell Metabolism.

Working in mice and in human cells, the researchers shed new light on how deposits of cholesterol contribute to macular degeneration and atherosclerosis and even blood vessel growth in some types of cancer.

Patients who have atherosclerosis often are prescribed medications to lower cholesterol and keep arteries clear. This study suggests that some of those same drugs could be evaluated in patients with macular degeneration.

“Based on our findings, we need to investigate whether vision loss caused by macular degeneration could be prevented with cholesterol-lowering eye drops or other medications that might prevent the buildup of lipids beneath the retina,” says senior investigator Rajendra S. Apte, MD, PhD.

The new research centers on macrophages, key immune cells that remove cholesterol and fats from tissues. In macular degeneration, the excessive buildup of cholesterol begins to occur as we age, and our macrophages begin to malfunction.

In the “dry” form of age-related macular degeneration, doctors examining the eye can see lipid deposits beneath the retina. As those deposits become larger and more numerous, they slowly begin to destroy the central part of the eye, interfering with the vision needed to read a book or drive a car.

As aging macrophages clear fewer fat deposits beneath the retina, the macrophage cells themselves can become bloated with cholesterol, creating an inflammatory process that leads to the formation of new blood vessels that can cause further damage. Those vessels characterize the later “wet” form of the disease.

“Ultimately, that inflammation creates a toxic mix of things that leads to new blood vessel growth,” Apte explains. “Most of the vision loss from ‘wet’ macular degeneration is the result of bleeding and scar-tissue formation related to abnormal vessel growth.”

As part of their research, the scientists identified a protein that macrophages need to clear fats and cholesterol. As mice and humans age, they make less of the protein, and macrophages become less effective at engulfing and removing fat and cholesterol.

Apte, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences, and his team found that macrophages, from old mice and in patients with macular degeneration, have inadequate levels of the protein, called ABCA1, which transports cholesterol out of cells. As a result, the old macrophages accumulated high levels of cholesterol and couldn’t inhibit the growth of the damaging blood vessels that characterize the “wet” form of the disorder.

But when the researchers treated the macrophages with a substance that helped restore levels of ABCA1, the cells could remove cholesterol more effectively, and the development of new blood vessels was slowed.

“We were able to deliver the drug, called an LXR agonist, in eye drops,” says first author Abdoulaye Sene, PhD, a post-doctoral fellow in the Apte lab. “And we found that we could reverse the macular degeneration in the eye of an old mouse. That’s exciting because if we could use eye drops to deliver drugs that fight macular degeneration, we could focus therapy only on the eyes, and we likely could limit the side effects of drugs taken orally.”

Sene and Apte also say that since macrophages are important in atherosclerosis and in the formation of new blood vessels around certain types of cancerous tumors, the same pathway also might provide a target for more effective therapies for those diseases.

“We have shown that we can reverse the disease cascade in mice by improving macrophage function, either with eye drops or with systemic treatments,” Apte says. “Some of the therapies already being used to treat atherosclerosis target this same pathway, so we may be able to modify drugs that already are available and use them to deliver treatment to the eye.”

Adapted from Washington University School of Medicine in St. Louis

View all news updates for macular degeneration


Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.

Twitter YouTube Facebook Shop for a Cause Pinterest Google+ Connect With Us